Karyopharm Therapeutics Inc
Research Karyopharm Therapeutics Inc (KPTI) on Bullrun: market cap USD 43.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKPTI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 43.55M
- Financial periodQ1 2026
- RevenueUSD 35.07M
- Net income-USD 22.39M
- Free cash flow-USD 22.73M
- Gross margin96.2%
Valuation Snapshot
latest market cap is USD 43.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 146.07M | -USD 196.04M | -USD 75.37M | 95.9% | -17.93 | USD 60.54M | USD 233.61M | -USD 292.93M |
| FY2024 | USD 145.24M | -USD 76.42M | -USD 127.63M | 95.9% | -14 | USD 62.48M | USD 194.52M | -USD 186.02M |
| FY2023 | USD 146.03M | -USD 143.10M | -USD 92.72M | n/a | -18.79 | USD 52.23M | USD 177.02M | -USD 136.21M |
| FY2022 | USD 157.07M | -USD 165.29M | -USD 149.67M | n/a | -2.02 | USD 135.19M | USD 179.89M | -USD 16.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 43.55M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 134.77M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 85.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 99.11M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 384.92M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 487.04M | n/a | n/a | n/a |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Karyopharm Therapeutics Inc's market cap?
Karyopharm Therapeutics Inc's market capitalization is USD 43.55M.
What does Karyopharm Therapeutics Inc do?
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).